Literature DB >> 20203284

Lymphangioleiomyoma cells and lymphatic endothelial cells: expression of VEGFR-3 in lymphangioleiomyoma cell clusters.

Kuniaki Seyama, Keiko Mitani, Toshio Kumasaka, Shiv K Gupta, Saji Oommen, Gang Liu, Jay H Ryu, Nicholas E Vlahakis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20203284      PMCID： PMC2843492          DOI： 10.2353/ajpath.2010.091239

Source DB:  PubMed          Journal:  Am J Pathol        ISSN： 0002-9440            Impact factor:   4.307


× No keyword cloud information.
  22 in total

1.  Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration.

Authors:  Aristotelis Astrinidis; Timothy P Cash; Deborah S Hunter; Cheryl L Walker; Jonathan Chernoff; Elizabeth P Henske
Journal:  Oncogene       Date:  2002-12-05       Impact factor: 9.867

Review 2.  The LAM cell: what is it, where does it come from, and why does it grow?

Authors:  G Finlay
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2004-04       Impact factor: 5.464

3.  Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score.

Authors:  K Matsui; M B Beasley; W K Nelson; P M Barnes; J Bechtle; R Falk; V J Ferrans; J Moss; W D Travis
Journal:  Am J Surg Pathol       Date:  2001-04       Impact factor: 6.394

4.  Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis.

Authors:  Toshio Kumasaka; Kuniaki Seyama; Keiko Mitani; Sanae Souma; Satoko Kashiwagi; Akira Hebisawa; Teruhiko Sato; Hajime Kubo; Kiyoshi Gomi; Kazutoshi Shibuya; Yoshinosuke Fukuchi; Koichi Suda
Journal:  Am J Surg Pathol       Date:  2005-10       Impact factor: 6.394

5.  Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM).

Authors:  Elena A Goncharova; Dmitry A Goncharov; Andrew Eszterhas; Deborah S Hunter; Marilyn K Glassberg; Raymond S Yeung; Cheryl L Walker; Daniel Noonan; David J Kwiatkowski; Margaret M Chou; Reynold A Panettieri; Vera P Krymskaya
Journal:  J Biol Chem       Date:  2002-06-03       Impact factor: 5.157

6.  Lymphangiogenesis in lymphangioleiomyomatosis: its implication in the progression of lymphangioleiomyomatosis.

Authors:  Toshio Kumasaka; Kuniaki Seyama; Keiko Mitani; Teruhiko Sato; Sanae Souma; Takashi Kondo; Seiji Hayashi; Masato Minami; Toshimasa Uekusa; Yoshinosuke Fukuchi; Koichi Suda
Journal:  Am J Surg Pathol       Date:  2004-08       Impact factor: 6.394

7.  Vascular endothelial growth factors C and D induces proliferation of lymphangioleiomyomatosis cells through autocrine crosstalk with endothelium.

Authors:  Rachel B Issaka; Saji Oommen; Shiv K Gupta; Gang Liu; Jeffrey L Myers; Jay H Ryu; Nicholas E Vlahakis
Journal:  Am J Pathol       Date:  2009-08-28       Impact factor: 4.307

Review 8.  Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma.

Authors:  Mary J C Hendrix; Elisabeth A Seftor; Angela R Hess; Richard E B Seftor
Journal:  Nat Rev Cancer       Date:  2003-06       Impact factor: 60.716

9.  Tissue inhibitor of metalloproteinase-3 downregulation in lymphangioleiomyomatosis: potential consequence of abnormal serum response factor expression.

Authors:  Xiaoning Zhe; Yan Yang; Sandhya Jakkaraju; Lucia Schuger
Journal:  Am J Respir Cell Mol Biol       Date:  2003-04       Impact factor: 6.914

10.  The transcription factor Prox1 is a marker for lymphatic endothelial cells in normal and diseased human tissues.

Authors:  Jörg Wilting; Maria Papoutsi; Bodo Christ; Kypros H Nicolaides; Constantin S von Kaisenberg; Jörg Borges; G Björn Stark; Kari Alitalo; Stanislav I Tomarev; Charlotte Niemeyer; Jochen Rössler
Journal:  FASEB J       Date:  2002-06-07       Impact factor: 5.191
View more
  5 in total

1.  Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).

Authors:  Elena A Goncharova; Dmitry A Goncharov; Melane Fehrenbach; Irene Khavin; Blerina Ducka; Okio Hino; Thomas V Colby; Mervyn J Merrilees; Angela Haczku; Steven M Albelda; Vera P Krymskaya
Journal:  Sci Transl Med       Date:  2012-10-03       Impact factor: 17.956

2.  Similar trends in serum VEGF-D levels and kidney angiomyolipoma responses with longer duration sirolimus treatment in adults with tuberous sclerosis.

Authors:  Izabela A Malinowska; Nancy Lee; Vidhya Kumar; Elizabeth A Thiele; David Neal Franz; Stephen Ashwal; Arthur Sagalowsky; Francis J Dimario; Drew Cutler; Darcy Krueger; Susana Camposano; Jan Paolini; Sandra L Dabora
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

3.  Evolution of lung pathology in lymphangioleiomyomatosis: associations with disease course and treatment response.

Authors:  Suzanne Miller; Iain D Stewart; Debbie Clements; Irshad Soomro; Roya Babaei-Jadidi; Simon R Johnson
Journal:  J Pathol Clin Res       Date:  2020-04-30

4.  Rapamycin-independent IGF2 expression in Tsc2-null mouse embryo fibroblasts and human lymphangioleiomyomatosis cells.

Authors:  Blanca E Himes; Kseniya Obraztsova; Lurong Lian; Maya Shumyatcher; Ryan Rue; Elena N Atochina-Vasserman; Stella K Hur; Marisa S Bartolomei; Jilly F Evans; Vera P Krymskaya
Journal:  PLoS One       Date:  2018-05-14       Impact factor: 3.240

5.  Clinical-Pathological Conference Series from the Medical University of Graz : Case No 170: A 33-year-old psychologist with severe dyspnea and right-sided chylothorax.

Authors:  Philipp K Bauer; Martin Flicker; Elisabeth Fabian; Holger Flick; Luka Brcic; Bernadette Liegl-Atzwanger; Michael Janisch; Michael Fuchsjäger; Horst Olschewski; Guenter J Krejs
Journal:  Wien Klin Wochenschr       Date:  2021-01       Impact factor: 1.704
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.